BioSpace News Archive

Drug Development

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023

Rhythm Pharmaceuticals, Inc. announced positive Phase 2 results and long-term extension trial data in hypothalamic obesity that are being presented as a late-breaking poster at The Obesity Society’s ObesityWeek® 2022 conference in San Diego.

November 2, 2022
·
14 min read
Business

LEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board

LEXEO Therapeutics, Inc. today announced a new executive appointment, as well as the development of a Scientific Advisory Board.

November 2, 2022
·
7 min read
Pharm Country

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,109, titled “Treatment of 22q11.2 Deletion Syndrome With Cannabidiol.”

November 2, 2022
·
6 min read
Deals

Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

Peak Bio Co., Ltd. today announced the completion of its business combination (the “Business Combination”) with Ignyte Acquisition Corp. (Nasdaq: IGNY) (“Ignyte”), a special purpose acquisition company.

November 2, 2022
·
7 min read
Genetown

Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics

Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.

November 2, 2022
·
8 min read
Business

EDAP TMS SA to Announce Third Quarter 2022 Financial Results on Wednesday, November 16th, 2022

EDAP TMS SA, the global leader in robotic energy-based therapies, announced that it will release its financial results for the third quarter ended September 30th after the markets close on Wednesday, November 16th, 2022.

November 2, 2022
·
1 min read
Business

Mainz Biomed Provides Third Quarter 2022 Update

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer provided an update on accomplishments during the third quarter which ended September 30, 2022.

November 2, 2022
·
9 min read
BioCapital

MaxCyte to Participate in Upcoming November 2022 Investor Conferences

MaxCyte, Inc. announced Company management will participate in the following investor conferences:

November 2, 2022
·
1 min read
Business

Medexus Schedules Second Quarter 2023 Conference Call

Medexus Pharmaceuticals plans to host a conference call at 8:00 am Eastern Time on Wednesday, November 9, 2022 to discuss Medexus’s results for its second quarter ended September 30, 2022.

November 2, 2022
·
4 min read
Business

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, announced that David P. Ryan, M.D. has been appointed to the company’s Board of Directors.

November 2, 2022
·
4 min read